Small-molecule inhibitors targeting BCR signaling such as Bruton tyrosine kinase (BTK) inhibitors (e.g., ibrutinib) have become the forefront of CLL therapeutics in the last decade. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.